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HEPATITIS
Durability of HBeAg seroconversion following antiviral
therapy for chronic hepatitis B: relation to type of therapy
and pretreatment serum hepatitis B virus DNA and
alanine aminotransferase
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Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is
durable in 80–90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg sero-
conversion following lamivudine are contradictory. We investigated the durability of response follow-
ing IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient
data.
Patients and methods: Twenty four centres included 130 patients in total with an HBeAg seroconver-
sion (HBeAg negative, antibodies to hepatitis B e antigen positive) at the end of antiviral therapy: 59
with lamivudine, 49 with interferon, and 22 with combination therapy. Relapse was defined as con-
firmed reappearance of HBeAg.
Results: The three year cumulative HBeAg relapse rate by the Kaplan-Meier method was 54% for
lamivudine, 32% for IFN, and 23% for combination therapy (p=0.01). Cox regression analysis identi-
fied pretreatment hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT), sex, and therapy as
independent predictive factors of post-treatment relapse; Asian race, previous therapy, centre, and
type of study were not predictive of relapse. The relative HBeAg relapse risk of lamivudine compared
with IFN therapy was 4.6 and that of combination therapy to IFN therapy 0.7 (poverall=0.01).
Conclusions: The durability of HBeAg seroconversion following lamivudine treatment was significantly
lower than that following IFN or IFN-lamivudine combination therapy. The risk of relapse after HBeAg
seroconversion was also related to pretreatment levels of serum ALT and HBV DNA, but independent of
Asian race.
L oss of hepatitis B e antigen (HBeAg), either spontaneouslyor following alpha interferon (IFN) therapy, significantlyimproves the clinical outcome and survival in chronic
hepatitis B virus (HBV) patients.1–3 Therefore, HBeAg loss with
seroconversion to antibodies to hepatitis B e antigen
(anti-HBe) has remained a major end point of antiviral
therapy in chronic HBV infection.
Monotherapy of 16–26 weeks of IFN is associated with loss
of serum HBeAg in 20–40% of patients, depending on baseline
alanine aminotransferase (ALT) levels.4 Several long term fol-
low up studies have been carried out in IFN responders show-
ing that IFN induced HBeAg seroconversion is sustained in
approximately 80–90% of patients.1 2 5–10 IFN responders are
more likely to clear hepatitis B surface antigen (HBsAg)
(23−86%) from serum than spontaneous seroconverters dur-
ing a median follow up of 3.8–9 years.1 2 5 6 10
HBeAg seroconversion is observed in 15–30% of patients after
1–2 years of lamivudine therapy.11–14 The clinical implication of
lamivudine induced HBeAg seroconversion is suggested to be
comparable with that of seroconversion following IFN
therapy.12 15 16 A relapse of HBeAgwas observed in 19% (8/42 ) of
patients with a response after lamivudine.16 In contrast, a single
centre cohort study showed a considerably higher percentage of
relapse, increasing to 50% (16/32) at two years.17
Combination therapy of 16–26 weeks results in HBeAg sero-
conversion in 29% of treatment naive patients and in 12% of
previous IFN non-responders.13 18 Reports on durability of sero-
conversion after IFN-lamivudine combination therapy reflect
only the first 16 weeks after therapy; similar relapse rates are
reported for responders after combination therapy (22%) com-
pared with lamivudine (23%) and IFN (25%) alone.19
Large comparative long term post-treatment studies are
lacking. To investigate the post-treatment durability of HBeAg
seroconversion following lamivudine, IFN monotherapy, or
IFN-lamivudine combination therapy, we performed a multi-
centre meta-analysis of individual patient data. As such a
study does not include randomisation, we have taken strict
precautions1 to minimise differences in outcome due to age,
sex, race, previous therapy, baseline ALT and HBV DNA, and
treatment centre. Multivariate analysis stratified for centre
was performed to obtain the current best estimate of the
durability of HBeAg seroconversion following the three thera-
pies; in addition, factors predictive of relapse were identified.
PATIENTS AND METHODS
Long term follow up data of chronic HBV patients with HBeAg
seroconversion after antiviral therapy were collected. We
contacted 53 centres that had patients with HBeAg seroconver-
sion in randomised controlled trials in which we participated
ourselves.13 18 20 21 In addition, five centres submitted data from
patients treated in cohort studies between 1998 and 2000.
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Abbreviations: IFN, interferon; HBV, hepatitis B virus; HBeAg, hepatitis
B e antigen; anti-HBe, antibodies to hepatitis B e antigen; ALT, alanine
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Patients who were HBV DNA and HBeAg positive before the
start of antiviral therapywere eligible if they seroconverted after
receiving lamivudine in a dose of at least 100 mg daily for 24
weeks or more, IFN monotherapy 30 million units per week for
at least 16 weeks, or IFN-lamivudine combination therapy for at
least 16 weeks.
HBeAg seroconversion was defined as loss of HBeAg,
appearance of anti-HBe, and HBV DNA negativity (hybridisa-
tion methodology) on two occasions at least one month apart,
at the end of lamivudine monotherapy, or within 12months of
initiation of IFN therapy in case of IFN mono or combination
therapy.9 Patients were excluded if at baseline there were
coinfections (hepatitis C virus, hepatitis D virus, or human
immunodeficiency virus), signs of decompensated cirrhosis
(defined as jaundice, variceal bleeding, ascites, or encephal-
opathy), or other causes of liver disease.
Virological and biochemical measurements
We collected follow up data on HBeAg, anti-HBe, HBV DNA,
HBsAg, and ALT, one month before the end of therapy, at the
end of therapy, three, six, and 12 months after the end of
therapy, and yearly thereafter.
Serum HBeAg, anti-HBe, and HBsAg were measured using
the routine commercially available immunoassays ImX (Abbott,
Chicago, Illinois, USA), Kodak Amerlite (Kodak Clinical and
Diagnostics, Amersham, UK), and DiaSorin (Vercelli, Italy).
Depending on the centre and date of measurement, serumHBV
DNA was measured using the solution hybridisation assay by
Abbott (detection limit 2×107 g eq/ml), bDNA assay (Chiron,
Emeryville, California,USA; limit of detection 7×105 g eq/ml), or
a hybrid capture tube assay (Digene,Murex,UK; detection limit
1.5×106 g eq/ml); all HBV DNA results were convertedto
Eurohep genome equivalents.22 ALT (IU/l) was expressed as
times the upper limit of normal (ULN).
Definition of relapse
Relapse was defined as reappearance of HBeAg in serum, con-
firmed by HBV DNA positivity in the same sample or by
HBeAg positivity in a consecutive sample. Relapse of HBV
DNA was defined as reappearance of HBV DNA in serum
above the cut off for the method employed.
Statistics
Results are presented as mean (SD). The cumulative relapse
rate for the total study population was calculated by the
Kaplan-Meier method with the log rank test for statistical
comparison between groups. To adjust for baseline differences
in patient viral and host characteristics, multivariate analysis
was performed by Cox regression analysis with the likelihood
ratio test for statistical significance, as described by Krogs-
gaard and colleagues.4 To account for a possible centre effect,
Cox regression was stratified by centre; centres with less than
four patients were clustered in one stratum. Furthermore,
interactions between therapy, Asian race, baseline ALT level,
baseline HBV DNA, sex, and previous therapy were investi-
gated. Sensitivity analysis was performed excluding one cen-
tre at a time. The level of significance was set to p<0.05.
To determine whether the duration of lamivudine therapy
influences relapse rates, a Cox regression analysis stratified for
centre was performed on the subset of patients on lamivudine
therapy (n=59) divided into two categories (<24–48 weeks,
n=26; >48 weeks, n=33).
RESULTS
Worldwide, 24 centres from 14 countries responded to our
request and collected follow up data of all of their patients in
the trials; 130 patients with chronic hepatitis B who had
responded to antiviral therapy with HBeAg seroconversion
were included. Baseline characteristics are presented in table
1. Fifty nine patients had received lamivudine, 49 IFN, and 22
combination therapy; 71 patients received the treatment as a
participant in an international randomised controlled trial.
Follow up until time of relapse or until the last observation
ranged from four weeks to seven years for both HBeAg and
HBV DNA. At the start of follow up, groups were comparable
regarding sex, age, and pretreatment serum levels of HBV
DNA and ALT. There were differences in the distribution of
race, previous antiviraltherapy, and participation in a ran-
domised controlled trial between the three groups.
Figure 1 shows the percentage of sustained HBeAg
seroconversion and HBV DNA negativity for the total study
population by KaplanMeier analysis. A statistically significant
higher relapse rate of HBeAg and/or HBV DNA positivity was
observed after the end of lamivudine monotherapy compared
with IFN monotherapy or combination therapy.
The results of the univariate analysis, shown in table 2, dem-
onstrate that lamivudine therapy, male sex, high pretreatment
HBV DNA, and low ALT are potential predictive factors for
relapse of HBeAg and HBV DNA in serum. Age, race, previous
antiviral therapy, centre, and study (randomised controlled trial
or cohort study) were not significantly related to outcome.
Multivariate Cox analysis stratified by centre showed that
high pretreatment HBV DNA, low ALT, lamivudine therapy, and
(male) sex were independent predictive factors of post-
treatment relapse (table 3). There were no significant interac-
tions. Sensitivity analysis excluding each centre one at a time
Table 1 Baseline characteristics of chronic hepatitis B e antigen (HBeAg) positive
patients prior to successful antiviral therapy, by therapy group
IFN (n=49) LAM (n=59) IFN+LAM (n=22)
Sex, male 36 (73%) 42 (71%) 14 (64%)
Age (y)* 41 (16) 37 (12) 43 (15)
Ethnicity
Caucasian, other 39 (80%) 19 (33%) 18 (82%)
Asian 10 (20%) 39 (66%) 3 (14%)
Log HBV DNA*† 8.4 (1.0) 8.7 (0.8) 8.5 (0.8)
ALT (×ULN)* 4.3 (2.4) 4.5 (4.2) 3.3 (2.5)
Previous therapy
IFN 9 (18%) 26 (44%) 8 (36%)
LAM 0 (0%) 4 (7%) 1 (5%)
Type of study
RCT 46 (94%) 10 (17%) 15 (68%)
Cohort 3 (6%) 49 (83%) 7 (32%)
*Means (SD)
†Corrected for the HBV DNA test used: Abbott or bDNA pg/ml are converted to Eurohep genome
equivalents/ml (g eq/ml).
IFN, interferon; LAM, lamivudine; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine
aminotransferase; ULN, upper limit of normal; RCT, randomised controlled trial.
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gave similar relative risks as the outcome in table 3. Subgroup
analysis for patients with or without previous antiviral therapy
(IFN and/or lamivudine) showed equal relapse risks in both
groups. In a further analysis, race remained included because of
the unequal distribution across therapies. Patients with lamivu-
dine induced HBeAg seroconversion showed a significantly
higher risk of relapse compared with HBeAg seroconverters fol-
lowing IFN or combination therapy. The relative HBeAg relapse
risk compared with IFN therapy was 4.6 (95% confidence inter-
val (CI) 1.4–14.5) for lamivudine monotherapy and 0.7
(0.1–3.9) for combination therapy (poverall=0.01).The relative risk
of an HBV DNA relapse in serum compared with IFN therapy
was 3.9 (95% CI 1.3–12) for lamivudine monotherapy and 0.6
(0.13–2.9) for combination therapy (poverall=0.010). The risk of
relapse over time for the three therapies corrected for pretreat-
ment HBV DNA, sex,and any possible race effect can be
calculated for a given patient. Figure 2 illustrates the risk of
relapse over time for a male Caucasian patient with a mean pre-
treatment HBV DNA level of 4×108 g eq/ml for three different
categories of baseline ALT levels.
The relative risk of relapse after lamivudine therapy was not
significantly influenced by the duration of therapy (p=0.28)
but a trend towards a diminished relapse rate with longer
treatment was found. The relative risk of a HBeAg relapse
Figure 1 Cumulative percentage of sustained hepatitis B e antigen (HBeAg) seroconversion (A) and hepatitis B virus (HBV) DNA negativity (B)
for the total study population. HBeAg relapse at one year of follow up was observed in 42% of lamivudine (LAM), in 21% of interferon (IFN),
and in 23% of combination therapy (IFN+LAM) treated patients, increasing to 54%, 32%, and 23% respectively after three years (poverall=0.01).
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Table 2 Relative risk (hazard rates) of relapse according to the univariate analysis
(Cox regression) stratified by centre
Variable
HBeAg relapse HBV DNA relapse
Relative risk
(95% CI)
p Value (log
likelihood)
Relative risk
(95% CI)
p Value (log
likelihood)
Therapy 0.0008 0.0005
IFN 1 1
LAM 7.4 (2.5–22.4) 0.0003 7.1 (2.4–20.1) 0.0002
Combination 1.3 (0.8–4.5) 0.68 1.1 (0.3–3.8) 0.87
Age (y) 1.00 (0.98–1.02) 0.87 1.00 (0.98–1.03) 0.70
Sex
Male 1
Female 0.4 (0.2–0.9) 0.02 0.5 (0.2–1.1) 0.05
Race
Caucasian 1 1
Asian 0.8 (0.3–2.3) 0.75 1.0 (0.4–2.6) 0.97
Previous therapy 0.24 0.05
None 1 1
IFN 1.3 (0.6–2.6) 0.49 1.4 (0.7–2.7) 0.37
LAM 3.9 (0.8–19.3) 0.11 6.6 (1.4–31.3) 0.02
Study type
RCT 1 1
Cohort 1.3 (0.3–5.6) 0.75 1.85 (0.5–6.8) 0.38
HBV DNA (log) 1.51 (1.04–2.21) 0.03 1.50 (1.03–2.19) 0.03
HBV DNA
HBV DNA <108 1 1
HBV DNA >108 2.2 (1.2–4.2) 0.01 2.1 (1.1–3.8) 0.02
ALT (×ULN) 0.04 0.07
<2 1 1
2–5 0.4 (0.2–0.9) 0.03 0.5 (0.2–1.0) 0.04
>5 0.4 (0.1–0.9) 0.02 0.4 (0.2–1.0) 0.04
Duration of lamivudine therapy 0.28 0.22
24–48 weeks 1 1
48–72 weeks 0.4 (0.2–1.2) 0.11 0.4 (0.2–1.1) 0.09
>72 weeks 0.5 (0.1–2.8) 0.45 0.7 (0.2–2.8) 0.57
IFN, interferon; LAM, lamivudine; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine
aminotransferase; ULN, upper limit of normal; RCT, randomised controlled trial
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compared with IFN therapy was 3.8 (95% CI 1.1–12.6) for
lamivudine monotherapy of 48 or more weeks and 14.7 (95%
CI 3.2–6.7) for lamivudine therapy of less than 48 weeks.
DISCUSSION
The durability of HBeAg seroconversion after lamivudine
therapy was reported to be 80–90% in the first studies
performed in Western countries.12 15 16 19 Recently, Song et al
observed a relapse of viral activity in half of responding patients
after withdrawal of lamivudine monotherapy in an Asian
cohort study.17 Ethnicity and duration of therapy prior to
seroconversion have been suggested to be predictive factors for
post-treatment relapse. In this study, comparing long term
post-treatment data in 130 responders after lamivudine, IFN,
and IFN-lamivudine combination therapy, lamivudine induced
HBeAg seroconversion was significantly less durable than
HBeAg seroconversion following IFN containing therapies,
independent of race. However, the pretreatment factors high
serum HBV DNA and low serum ALT were associated with a
higher relapse rate; duration of therapy less than 48 weeks may
also be a factor although this was not significant in our study.
The US studies comprised a low number of patients with
HBeAg seroconversion, 11 and five, respectively, with a follow
up of 4–12 months. The studies reported by Schiff et al in two
abstracts only included patients who remained HBeAg
negative three months after the end of therapy, thereby
excluding early relapsers.16 We have tried to increase the accu-
racy of the estimate of the durability of HBeAg seroconversion
by including a large number of responders in the study, by
prolonging the duration of follow up to three years, and by
thorough statistical analysis. We corrected for differences in
baseline characteristics by using multivariate analysis. The
finding that our results were valid for each centre separately
should markedly increase the confidence in the results.
However, factors that were not part of the multivariate
analysis may still be of relevance. It is possible that patients
undergoing relapse are more likely to return to their physician
than patients with a sustained response. We collected data
from more than 90% of responders of the centres that partici-
pated, minimising the likelihood of selection bias. Further-
more, this potential pitfall would affect all three therapies and
should therefore not influence the relative risk.
Table 3 Relative risks (hazard rates) of relapse according to the multivariate
analysis (Cox regression stratified by centre and correcting for sex, HBV DNA, ALT,
and race)
Variable
HBeAg relapse HBV DNA relapse
Relative risk
(95% CI)
p Value
(log likelihood)
Relative risk
(95% CI)
p Value
(log likelihood)
Therapy 0.01 0.01
IFN 1 1
LAM 4.6 (1.4–14.5) 0.01 3.9 (1.3–12.1) 0.02
Combination 0.7 (0.1–3.9) 0.72 0.6 (0.1–2.9) 0.50
Sex
Male 1 1
Female 0.4 (0.2–0.9) 0.04 0.5 (0.2–1.2) 0.12
Race
Caucasian 1 1
Asian 0.8 (0.3–2.4) 0.74 1.1 (0.4–3.0) 0.84
Log HBV DNA 1.61 (1.03–2.52) 0.03 1.7 (1.1–2.6) 0.02
ALT (×ULN) 0.03 0.05
<2 1 1
2–5 0.4 (0.2–0.9) 0.02 0.4 (0.2–0.9) 0.03
>5 0.3 (0.1–0.8) 0.01 0.4 (0.2–0.9) 0.03
IFN, interferon; LAM, lamivudine; HBV, hepatitis B virus; ALT, alanine aminotransferase; ULN, upper limit of
normal.
Figure 2 Cumulative percentage of relapse for the three therapies, corrected for the baseline factors pretreatment hepatitis B virus (HBV)
DNA, alanine aminotransferase (ALT), sex, and race, can be calculated for a specific patient using the results of the Cox regression (the
estimated relative risks and baseline hazard). Here, the risk is illustrated for a male Caucasian patient with a mean pretreatment HBV DNA
level of 4×108 g eq/ml after lamivudine (LAM), interferon (IFN), and IFN-lamivudine (IFN+LAM) combination therapy for three different ALT
values: (A) ALT <2×upper limit of normal (ULN), (B) ALT 2–5×ULN, (C) >5×ULN. Relapse rates are particularly high in patients with a baseline
ALT <2×ULN.
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The HBeAg relapse rate following IFN therapy in this study
population (32% in three years) may appear high. However,
when corrected for mean HBV DNA levels and stratified for
ALT category, the post-treatment relapse rate following IFN
(fig 2) was in accordance with the literature.1 2 5–10
Serum HBV DNA and ALT have been identified as predictors
of response to antiviral therapy in chronic HBV infection.1 23
More recently, the degree of ALT elevation was found to be the
most powerful predictor for HBeAg seroconversion.13 24 In this
study, pretreatment HBV DNA levels were the major predictor
for sustained response. In contrast with Song and colleagues,17
we also found a significant predictive value of pretreatment ALT
levels for the durability of HBeAg seroconversion (higher base-
line ALT—lower chance of relapse).
Differences in relapse following lamivudine and IFN therapy
suggest a lack of an efficient immune control following HBeAg
seroconversion in lamivudine treated patients. Resolution of
acute hepatitis B is associated with a strong humoral and cellu-
lar immune response which is often maintained for years by
persistence of minute amounts of HBV in liver or serum.25–27 In
contrast with acute HBV infections, chronic HBV is generally
associated with a weak and ineffective antiviral T cell
response.26 28 Spontaneous exacerbations and antiviral therapy
with IFN can elucidate a significant T helper cell response pre-
ceding HBeAgseroconversion.29–31 Although Boni et al reported a
restored HBV specific T cell response following the strong
decline in HBV DNA levels in lamivudine treated patients,
HBcAg specific T cell response remained undetectable during
lamivudine therapy in another study.31 32 The differences in
relapse after lamivudine and IFN therapies in our study suggest
induction of immune control as an essential element for long
term durability of HBeAg seroconversion.
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